Scilex Holding (SCLXW) Non-Current Deffered Revenue (2021 - 2026)

Scilex Holding (SCLXW) recorded quarterly Non-Current Deffered Revenue of $1.9 million in Q1 2026, down 4.7% quarter-over-quarter from $2.0 million in Q4 2025, and down 16.99% on a YoY basis from $2.3 million in Q1 2025.

Scilex Holding (SCLXW) Non-Current Deffered Revenue (2021 - 2026) Analysis & Trends

Scilex Holding's Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $1.9 million for Q1 2026.

  • In Q1 2026, Non-Current Deffered Revenue fell 16.99% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 16.99% YoY), while the FY2025 annual figure was $2.0 million, down 16.63% from the prior year.
  • Non-Current Deffered Revenue was $1.9 million for Q1 2026 at Scilex Holding, down from $2.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $5.2 million in Q1 2022 to a low of $1.9 million in Q1 2026.
  • Historically, Non-Current Deffered Revenue has averaged $3.1 million across 5 years, with a median of $2.8 million in 2024.
  • The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue changed 0.0% in 2022, then tumbled 41.93% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $3.4 million in 2022, then declined by 14.53% to $2.9 million in 2023, then retreated by 15.44% to $2.4 million in 2024, then declined by 16.63% to $2.0 million in 2025, then fell by 4.7% to $1.9 million in 2026.
  • The last three Non-Current Deffered Revenue figures came in at $1.9 million (Q1 2026), $2.0 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn -
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn -
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn -
10 Scilex Holding - - 4.15 Mn 1.95 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.95 Mn
Dec 31, 2025 2.04 Mn
Sep 30, 2025 2.14 Mn
Jun 30, 2025 2.24 Mn
Mar 31, 2025 2.34 Mn
Dec 31, 2024 2.45 Mn
Sep 30, 2024 2.56 Mn
Jun 30, 2024 2.67 Mn
Mar 31, 2024 2.78 Mn
Dec 31, 2023 2.90 Mn
Sep 30, 2023 3.01 Mn
Jun 30, 2023 3.14 Mn
Mar 31, 2023 3.26 Mn
Dec 31, 2022 3.39 Mn
Sep 30, 2022 5.19 Mn
Jun 30, 2022 5.19 Mn
Mar 31, 2022 5.19 Mn
Sep 30, 2021 5.19 Mn
Jun 30, 2021 5.19 Mn
Mar 31, 2021 5.19 Mn